Skip to main content
MyDeficiencies

Benztropine

Anticholinergic antiparkinsonian agent (tropine ether, antimuscarinic/antihistaminic)

Also sold as Cogentin.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Benztropine is an old drug, approved in the 1950s, and its current FDA label contains almost no quantified pharmacokinetic data: no absorption percentage, no named metabolizing enzyme, no elimination route, and no half-life appear anywhere in the Clinical Pharmacology section retrieved for this review. A 1999 pharmacology review of anticholinergic Parkinson's-disease drugs (Brocks, J Pharm Pharm Sci ) makes the same point explicitly, describing this entire drug class, including benztropine, as "overlooked... from a pharmacokinetic perspective," with little human PK data published at all. No CYP450 induction or inhibition is documented. Tested against every classical depletion mechanism, none returned drug-specific evidence of a named-nutrient effect: no chelation, no gastric-pH-mediated absorption interference, no hepatic-enzyme-induction-driven catabolism, no renal tubular wasting, no cofactor antagonism, no dilutional or aldosterone/ADH-type hormonal disturbance, and no documented classical vitamin or mineral deficiency, specific or class-level, survived an exhaustive multi-phrasing literature search. The only present mechanisms are the drug's own well-documented peripheral anticholinergic side effects, reduced GI motility and secretions, and reduced appetite from severe dry mouth and nausea, which are carried forward below, not as classical nutrient findings, but into the Gut microbiome risk category where they belong mechanistically.

Anticholinergic antiparkinsonian agent (tropine ether, antimuscarinic/antihistaminic) · ATC N04AC01 · also sold as Cogentin · reviewed 2026-10-01. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Benztropine in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Not graded — disclosed evidence gap

See study details

No benztropine-specific or defensible class-level evidence, at any tier, addresses direct effects on mitochondrial structure, membrane integrity, electron transport, or biogenesis, and no circulating consumer claim about benztropine and mitochondria was found to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: The Step 7 dual condition is met: no Tier B/C evidence exists to support even a yellow grade, and no circulating claim exists to rebut as white. This repair pass re-ran a dedicated PubMed search-listing query for "benztropine mitochondria," which returned three results, all reviewed individually rather than taken on title alone: a 1974 rat-striatum dopamine-accumulation comparison (Nose & Segawa), a 1981 study of covalent dopamine-protein interactions in rat brain that notes benztropine blocks dopamine reuptake (Davies & Abood), and a 1982 synaptosomal monoamine-oxidase kinetics paper (Katz) that mentions "free mitochondria" only as a comparison enzyme source unrelated to benztropine. None measures benztropine's effect on mitochondrial structure, membrane integrity, electron transport, or biogenesis, so none clears the Tier B bar for this specific category even though benztropine was technically in two of the three cohorts. A broader prior-pass Europe PMC query (25 results) likewise surfaced only Parkinson's-disease-intrinsic mitochondrial pathology (disease-intrinsic, excluded per Hard Rule 2), not benztropine-caused effects. This pass's follow-up attempts to the Europe PMC REST API, Crossref API, Semantic Scholar API, and OpenAlex works-search endpoint for a second independently phrased confirmation were repeatedly rejected with HTTP 429 across multiple spaced retries (60-110 second waits) and could not be completed; disclosed as a tooling limitation, not folded silently into the gap finding. WebSearch was unavailable all pass (200/200 budget confirmed exhausted on the first call).

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, protective direction in a combination-therapy animal model, not a depletion signal

Yellow — Low

See study details

A 2025 rat study found that benztropine, combined with the anticoagulant dabigatran, reduced brain oxidative-damage markers and raised glutathione in cobalt-chloride-induced parkinsonism; benztropine was genuinely in the studied cohort, but only as part of a two-drug combination in a disease model, not alone and not in humans, so this is graded on mechanistic plausibility in the protective/reverse direction, not as evidence of benztropine-caused oxidative stress or depletion.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No human data and no benztropine-monotherapy arm's oxidative-stress outcome could be confirmed from the metadata retrieved in this review; full text was not reachable this pass (see Sources). No study was found reporting benztropine use associated with increased oxidative stress in any species.
  • At-risk subgroups: Not applicable: this is an animal disease-model finding in the protective direction, not a human risk signal, so no at-risk human subgroup is identified.
  • Counter-evidence on record: A separate PubMed search for benztropine and mitochondria (a conceptually adjacent category, graded independently below per Hard Rule 7) returned three older pharmacology papers on dopamine-reuptake kinetics with no oxidative-stress or mitochondrial-structure finding, and none contradicts or supports this entry directly. No study was found measuring oxidative-stress markers in benztropine-treated humans, positive or negative.

Regulatory status

No oxidative-stress marker, antioxidant status, or redox-related laboratory finding appears in the FDA label retrieved for this review. This entry rests entirely on the non-regulatory literature below.

Population evidence

Tier B, drug-specific, animal model: Abdelmissih S, Rashed LA, Negm MS, Sayed WM, Mahmoud H, Emorsy S. "Dabigatran Combined With Benztropine Ameliorates Cobalt Chloride-Induced Parkinsonism in Rats, Restores Protease-Activated Receptor 1 (PAR1), and Mitigates Oxidative Stress." Cureus. 2025 Mar 12;PMID 40225545, DOI 10.7759/cureus.80486. Rats received oral cobalt chloride for 60 days to induce a parkinsonism model, with benztropine and/or dabigatran introduced on day 31; brain tissue was analyzed for dopamine and adenosine receptor signaling, protease-activated receptor 1 (PAR1), endothelin-1, oxidative-stress markers, and glutathione. The combined benztropine-plus-dabigatran arm restored motor function and PAR1 expression and reduced oxidative damage relative to the cobalt-only group. The record confirms benztropine was dosed in this cohort (satisfying the Hard Rule 6 cohort test), but the abstract-level data retrieved in this review does not isolate a benztropine-only arm's effect on the oxidative-stress markers from the combination effect, which is why this is capped at yellow rather than orange.

Mechanism

Not fully named at the abstract level. The study frames the effect through thrombin-pathway (PAR1) inhibition from dabigatran and dopaminergic-adenosinergic modulation, with benztropine's own anticholinergic/antihistaminic pharmacology a plausible but unconfirmed contributor to the combination's antioxidant effect; no electron-transport-chain, mitochondrial, or direct free-radical-scavenging mechanism specific to benztropine is identified.

Counter-evidence held on record

This is an animal, combination-therapy, disease-model finding in the protective direction, not evidence that benztropine depletes antioxidant capacity or causes oxidative stress in people, and not a finding that isolates benztropine's own contribution from dabigatran's. No antioxidant supplement, vitamin, or dose is implied or recommended by this entry in either direction.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No benztropine-specific or defensible class-level evidence addresses copper status or metabolism, and no circulating consumer claim about benztropine and copper was found to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: The Step 7 dual condition is met: no Tier B/C evidence exists to support even a yellow grade, and no circulating claim exists to rebut as white. The FDA label contains no copper-related mechanism, laboratory table, or warning. This repair pass re-ran a dedicated PubMed search-listing query, "benztropine" AND (copper OR ceruloplasmin OR "ATP synthase" OR "electron transport" OR "oxygen delivery" OR hemoglobin), which returned the PubMed homepage's generic "Trending Articles" fallback, a true zero-result signal (confirmed against the same fallback behavior seen elsewhere in this dossier), with no copper-related hit of any kind. The earlier-pass 25-result Europe PMC broad query (including "mineral" and "deficiency") likewise contained no copper-specific finding. No absorption-chelation or renal-wasting mechanism implicating copper is present in the pharmacokinetic prescreen. This pass's follow-up attempts to the Europe PMC REST API, Crossref API, Semantic Scholar API (both its search and single-paper-by-PMID endpoints), and OpenAlex works-search endpoint for an independently phrased second confirmation were repeatedly rejected with HTTP 429 across multiple spaced retries and could not be completed; disclosed as a tooling limitation. WebSearch was unavailable all pass (200/200 budget confirmed exhausted).

Iron

Not graded — disclosed evidence gap

See study details

No benztropine-specific or defensible class-level evidence addresses iron status, hemoglobin, or hematologic parameters, and no circulating consumer claim about benztropine and iron was found to rebut.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: The Step 7 dual condition is met. The FDA label was reviewed specifically for hematology, hemoglobin, hematocrit, anemia, and ferritin terms and contains no such laboratory-abnormality tables or mechanism language. This repair pass re-ran a dedicated PubMed search-listing query, "benztropine" AND (copper OR ceruloplasmin OR "ATP synthase" OR "electron transport" OR "oxygen delivery" OR hemoglobin), which returned a true zero-result fallback, with no hemoglobin- or iron-related hit. A separate query, benztropine AND (copper OR iron OR ATP OR hypoxia OR "oxygen delivery"), surfaced one title-level false lead reviewed and excluded: "Benztropine methanesulfonate, iron sulfate, and benzocaine intoxications" (N Y State J Med, 1961, PMID 14447407), a decades-old multi-substance poisoning case report in which iron sulfate and benzocaine appear to be separately co-ingested products, not a pharmacological benztropine-iron interaction; the full text could not be opened to confirm this reading (the PubMed article page returned a reCAPTCHA bot-verification challenge instead of content on this pass), so it is disclosed here as a reviewed-but-unconfirmed exclusion rather than silently dropped. No absorption-chelation, renal-wasting, or GI-bleeding mechanism implicating iron is present in the pharmacokinetic prescreen (benztropine's labeled GI effects are motility- and secretion-related, constipation and reduced secretions, not mucosal injury or bleeding). Further follow-up queries to Europe PMC, Crossref, Semantic Scholar, and OpenAlex search endpoints were repeatedly rejected with HTTP 429 across multiple spaced retries during this pass and could not be completed; disclosed as a tooling limitation.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, anticholinergic motility/secretory pathway, not directly measured for this drug

Yellow — Low

See study details

Benztropine's own peripheral anticholinergic action, a drug-caused side effect distinct from its intended antiparkinsonian/EPS-treatment pharmacology, slows GI transit and reduces secretions; this is mechanistically plausible as a driver of gut dysbiosis, but no study has directly measured gut microbiome composition in benztropine users, so this rests on mechanism plus class extrapolation, not a confirmed microbiome finding.

Full detail, limits and 4 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No study was found measuring gut microbiome composition directly in benztropine users, positive or negative; the motility mechanism is well-documented at the label level, but the actual microbiome outcome remains unmeasured for this specific drug, a genuine evidence gap on the outcome side of this entry.
  • At-risk subgroups: Patients on concurrent anticholinergic or antipsychotic co-therapy (as in the reported case of aripiprazole plus benztropine), the elderly, and anyone with pre-existing constipation or reduced mobility, where anticholinergic antimotility effects compound.
  • Counter-evidence on record: No source was found contradicting the motility/secretory mechanism itself, which is well established at the label level. No study was found reporting benztropine use with normal or unaffected gut microbiome markers either; this reflects the absence of any direct microbiome measurement for this drug, not a tested-and-refuted finding.

Regulatory status

The FDA label lists paralytic ileus, constipation, vomiting, and nausea as adverse reactions, and documents severe dry mouth sufficient to impair swallowing or speech and cause appetite loss, attributed to benztropine's anticholinergic action (isolated-ileum potency approximately equal to atropine). Tier A and drug-specific for the motility/secretory mechanism; the label does not address gut microbiome composition itself.

Population evidence

(1) Tier B, drug-specific: a 2025 case report (Qatar Med J, PMID 40792242) titled "A giant fecaloma causing stercoral colitis secondary to aripiprazole and benztropine" names benztropine among the causative medications in a patient's history. The full text could not be opened in this review (access-limited by repeated proxy rate-limiting, disclosed in Sources); causal weight cannot be apportioned between benztropine and the co-administered aripiprazole from the title/metadata retrieved, so this is read as supporting evidence for the motility mechanism, not as proof of benztropine-alone causation. (2) Tier C, class-level: two population studies link higher anticholinergic/antimuscarinic drug burden, scored on standard burden indices on which benztropine is conventionally rated a high-potency antimuscarinic agent, to altered microbiome composition: Wei et al. 2025 (PMID 41211602), a representative U.S. national survey linking polypharmacy and anticholinergic burden to oral microbiome composition; and Gemikonakli et al. 2023 (PMID 36124741), showing Drug Burden Index-scored anticholinergic/sedative polypharmacy alters the gut microbiome in aged mice, reversible with deprescribing. Neither retrieved abstract snippet individually named benztropine in its specific cohort, so the Hard Rule 6 cohort test is satisfied only by standard burden-scale convention, not by a confirmed line-item, which is the reason this entry is capped at yellow.

Mechanism

Named: reduced cholinergic tone slows gastrointestinal transit and reduces luminal secretions (label-documented, antimuscarinic potency approximately equal to atropine in isolated-ileum testing), a recognized upstream driver of altered gut microbial composition in the broader anticholinergic-burden literature.

Counter-evidence held on record

This entry reflects a real, drug-caused side-effect mechanism, slowed GI motility and reduced secretions from benztropine's own peripheral anticholinergic action, not its intended central antiparkinsonian/EPS-treatment pharmacology, and not a measured gut microbiome deficiency. No probiotic, fiber, or other supplement dose is implied or recommended by this entry. The practical response to this pathway is clinical bowel-function monitoring and anticholinergic-burden review, not nutrient repletion.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No benztropine-specific or defensible class-level evidence addresses hemoglobin, hematocrit, red-cell mass, arterial oxygenation, or tissue oxygen delivery, and no circulating consumer claim about benztropine and oxygen delivery was found to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: The Step 7 dual condition is met. Benztropine has no labeled hemodynamic, cardiac-output, or respiratory-drive mechanism (unlike, for example, a beta-blocker's intended reduction in heart rate and myocardial oxygen demand, which would need to be excluded under Hard Rule 2 rather than graded here; no analogous intended mechanism exists for benztropine to begin with). This repair pass re-ran a dedicated PubMed search-listing query, "benztropine" AND (copper OR ceruloplasmin OR "ATP synthase" OR "electron transport" OR "oxygen delivery" OR hemoglobin), which returned a true zero-result fallback with no oxygen- or hemoglobin-related hit. The 25-result Europe PMC broad query from the prior pass likewise contained no oxygen-delivery-specific finding for benztropine. Further follow-up queries to Europe PMC, Crossref, Semantic Scholar, and OpenAlex search endpoints were repeatedly rejected with HTTP 429 across multiple spaced retries during this pass and could not be completed; disclosed as a tooling limitation. WebSearch was unavailable all pass (200/200 budget confirmed exhausted).

ATP production

Not graded — disclosed evidence gap

See study details

No benztropine-specific or defensible class-level evidence addresses mitochondrial ATP synthesis or cellular energy output, and no circulating consumer claim about benztropine and ATP or "low energy" was found to rebut.

Full detail, limits and 2 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: The Step 7 dual condition is met. This repair pass re-ran a dedicated PubMed search-listing query, "benztropine" AND (copper OR ceruloplasmin OR "ATP synthase" OR "electron transport" OR "oxygen delivery" OR hemoglobin), which returned a true zero-result fallback with no ATP- or electron-transport-related hit. The 25-result Europe PMC broad query from the prior pass likewise contained no ATP- or energy-metabolism-specific finding for benztropine. A related 2025 rat study did surface for a different category (Oxidative stress, graded yellow above, Abdelmissih et al., PMID 40225545) but its reported outcome measures, PAR1, endothelin-1, oxidative-stress markers, and glutathione, do not include an ATP, mitochondrial-synthesis, or cellular-energy-output measure, so it does not carry over to this entry per Hard Rule 7's bar on collapsing adjacent categories together. Fatigue and sedation are not listed as prominent labeled effects of benztropine (its labeled CNS effects are toxic psychosis, confusion, hallucinations, depression, and nervousness, at higher doses or in susceptible patients), so no fatigue-based consumer "low energy" claim was anticipated or located either. Further follow-up queries to Europe PMC, Crossref, Semantic Scholar, and OpenAlex search endpoints were repeatedly rejected with HTTP 429 across multiple spaced retries during this pass and could not be completed; disclosed as a tooling limitation.

How the body handles this medication

Mechanism of action
Benztropine mesylate possesses both anticholinergic and antihistaminic effects; in the isolated guinea pig ileum its anticholinergic activity is about equal to that of atropine. Only the anticholinergic activity is considered therapeutically relevant to parkinsonism.FDA label, DailyMed SPL (Cipla USA Inc.), Clinical Pharmacology
Absorption / metabolism / elimination
Not quantified in the current FDA label retrieved for this review: no absorption percentage, named metabolizing pathway, excretion route, or half-life is given. This reflects an old-NDA drug (initial approval in the 1950s) predating modern human ADME study requirements, not a confirmed absence of such processes in the body.FDA label, DailyMed SPL, Clinical Pharmacology / Description
CYP450 enzymes
No CYP450 induction or inhibition data for benztropine appear in the retrieved label. This absence is noted as a gap in available labeling, not as evidence that no such interaction exists.FDA label, DailyMed SPL
Class-level pharmacokinetics (not benztropine-stratified)
A 2002 review of Parkinson's-disease drug pharmacokinetics describes centrally-acting antimuscarinic agents as a class: "rapid absorption after oral intake, large volume of distribution and low clearance relative to hepatic blood flow, with extensive metabolism." This is class-level, not individually confirmed for benztropine.Deleu, Northway, Hanssens, Clin Pharmacokinet 2002;41(4):261-309
Literature consensus on data scarcity
A dedicated pharmacokinetic review of anticholinergic Parkinson's-disease drugs concludes there is "little pharmacokinetic information available" for this class, including benztropine, and frames it as "an overlooked class of drugs from a pharmacokinetic perspective."Brocks DR, J Pharm Pharm Sci 1999;2(2):39-46, PMID 10952768
GI motility / secretory effects (drug-caused side effect, not intended target)
Labeled adverse reactions include paralytic ileus, constipation, vomiting, and nausea; severe dry mouth may impair swallowing or speech and cause appetite loss; urinary retention and dysuria are also documented. These are peripheral consequences of benztropine's own anticholinergic action, not its intended central antiparkinsonian/EPS-treatment effect, and are the mechanistic basis for the Gut microbiome risk entry below.FDA label, DailyMed SPL, Adverse Reactions
All references used above
  1. Benztropine Mesylate Tablets, full prescribing information. — FDA label, DailyMed SPL, Cipla USA Inc. Regulatory label; Tier A.
  2. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, code N04AC01 (Benzatropine). — Confirms ATC code, class (ethers of tropine or tropine derivatives), and DDD (2 mg oral). Regulatory reference index; Tier A.
  3. Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. — J Pharm Pharm Sci. 1999;2(2):39-46. PMID 10952768. Pharmacology review covering benztropine and related agents. Tier B.Access note: full abstract text could not be retrieved; the PubMed individual-article endpoint and the Europe PMC REST API both returned no renderable content or repeated HTTP 429 responses during this review. Title, journal, year, and PMID were confirmed via a PubMed search-listing page.
  4. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. — Clin Pharmacokinet. 2002;41(4):261-309. doi:10.2165/00003088-200241040-00003. Class-level narrative review of Parkinson's-disease drug classes including centrally-acting antimuscarinics; not individually stratified to benztropine. Tier C for drug-specific claims; used here only for general PK-basis context.
  5. A giant fecaloma causing stercoral colitis secondary to aripiprazole and benztropine. — Qatar Med J. 2025. PMID 40792242. Case report naming benztropine (in combination with aripiprazole) in the patient's medication history. Tier B.Access note: full text/abstract could not be opened; the Europe PMC REST API and the PubMed individual-article endpoint both returned repeated HTTP 429 responses on every attempt during this review. Title, journal, year, and PMID were confirmed via an Europe PMC search-listing query. Causal weight cannot be apportioned between benztropine and the co-administered aripiprazole from the metadata retrieved; author names were not confirmed and are omitted rather than guessed.
  6. Wei K, Yang Y, Chen C, Yang Y, Hu K, Chen Q. Polypharmacy, anticholinergic burden and oral microbiome among U.S. middle-aged and older adults: a representative national survey. — 2025. PMID 41211602. Class-level (anticholinergic burden score across many agents); individual-agent cohort breakdown not confirmed from the retrieved abstract snippet. Tier C, class extrapolation.Access note: benztropine's individual inclusion in this cohort is inferred from standard anticholinergic-burden-scale conventions, not confirmed line-by-line; full text was not opened due to proxy rate-limiting during this review.
  7. Gemikonakli G, Mach J, Zhang F, Bullock M, Tran T, El-Omar E, Hilmer SN. Polypharmacy With High Drug Burden Index (DBI) Alters the Gut Microbiome Overriding Aging Effects and Is Reversible With Deprescribing. — 2023. PMID 36124741. Class-level (Drug Burden Index antimuscarinic component, aged-mouse model); individual-agent cohort breakdown not confirmed from the retrieved abstract snippet. Tier C, class extrapolation.Access note: same as above; full text was not opened due to proxy rate-limiting during this review.
  8. Abdelmissih S, Rashed LA, Negm MS, Sayed WM, Mahmoud H, Emorsy S. Dabigatran Combined With Benztropine Ameliorates Cobalt Chloride-Induced Parkinsonism in Rats, Restores Protease-Activated Receptor 1 (PAR1), and Mitigates Oxidative Stress. — Cureus. 2025 Mar 12. PMID 40225545. DOI 10.7759/cureus.80486. Rat model, oral cobalt chloride x 60 days with benztropine and/or dabigatran from day 31; benztropine confirmed in the dosed cohort. Tier B, drug-specific animal/mechanistic study. Basis for the Oxidative stress yellow entry above, added in this repair pass.Access note: full text was not opened this pass; record retrieved and abstract reconstructed via the OpenAlex per-work lookup endpoint (https://api.openalex.org/works/pmid:40225545) after the PubMed article page and Semantic Scholar's paper-by-PMID endpoint were both rate-limited (HTTP 429). The reconstructed abstract does not isolate a benztropine-monotherapy arm from the combination arm, noted in the entry above.
  9. Benztropine methanesulfonate, iron sulfate, and benzocaine intoxications. — N Y State J Med. 1961. PMID 14447407. Title-level false lead surfaced by this pass's Iron-category search and reviewed, not cited as supporting evidence: reads as a multi-substance poisoning/overdose case report (separate co-ingested products), not a pharmacological benztropine-iron interaction. Full text could not be confirmed.Access note: the PubMed article page returned a reCAPTCHA bot-verification challenge instead of article content on this pass; the exclusion above is based on the title and publication format alone and is disclosed as unconfirmed rather than asserted as fact.
  10. Nose T, Segawa T. A comparison of the inhibitory effects of certain antiparkinsonian agents on dopamine accumulation into the rat striatum. — 1974. Title-level false lead surfaced by this pass's Mitochondrial-burden search and reviewed: dopamine-reuptake pharmacology, not a mitochondrial structure/function finding. Not cited as supporting evidence.
  11. PubMed search-listing queries documenting negative evidence (original pass). — "benztropine nutrient" (0 results); "benztropine AND (mitochondria OR mitochondrial OR oxidative stress OR copper OR iron OR ATP OR microbiome OR hemoglobin OR hematocrit OR oxygen)" (0 results, confirmed by PubMed's zero-result "trending articles" fallback page); "benztropine AND (vitamin OR folate OR magnesium OR calcium OR zinc OR potassium OR sodium OR vitamin B12 OR vitamin D)" (0 results, same fallback). Negative-evidence search documentation for the Ungraded entries above.
  12. PubMed search-listing queries documenting fresh-pass results (this repair pass, 2026-10-01). — "benztropine mitochondria" (3 results, reviewed, none on point); "benztropine AND oxidative stress" (2 results: an unrelated multiple-sclerosis biomarker paper, and the Abdelmissih et al. 2025 study cited above); "benztropine AND (copper OR ceruloplasmin OR ATP synthase OR electron transport OR oxygen delivery OR hemoglobin)" (true zero-result fallback); "benztropine AND (copper OR iron OR ATP OR hypoxia OR oxygen delivery)" (7 results, reviewed individually, none on point for copper/ATP/oxygen, one title-level false lead for iron, cited above). Negative and positive search documentation for this pass's category re-review.
  13. Europe PMC REST API search, query "benztropine AND (nutrient OR vitamin OR mineral OR deficiency)." — 25 results reviewed individually; none drug-specific to a nutrient/category claim except the fecaloma case report above. Several results concerned Parkinson's-disease-intrinsic pathology (vitamin D and PD mortality; oxidative stress/ferroptosis in PD) and were excluded as disease-intrinsic, not benztropine-caused, per Hard Rule 2. Negative/near-negative-evidence search documentation.
  14. PubMed search-listing query, "anticholinergic burden gut microbiome." — Surfaced the two class-level population studies cited above (Wei et al. 2025; Gemikonakli et al. 2023). Search documentation for the Gut microbiome risk entry.